{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:17:47Z","timestamp":1792034267962,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ekir.2024.06.020","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:40:02Z","timestamp":1718905202000},"page":"2648-2656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab"],"prefix":"10.1016","volume":"9","author":[{"given":"Franz","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Al-Dakkak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Anokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.06.020_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"Raina","year":"2019","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ekir.2024.06.020_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.06.020_bib3","first-page":"347","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2024.06.020_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of atypical hemolytic uremic syndrome: A systematic literature review","volume":"12","author":"Yan","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ekir.2024.06.020_bib5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.06.020_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2024.06.020_bib7","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","article-title":"Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes","volume":"14","author":"Ariceta","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2024.06.020_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.06.020_bib9","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","article-title":"Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2024.06.020_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.06.020_bib14","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.06.020_bib15","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.06.020_bib16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","article-title":"The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab","volume":"36","author":"Tanaka","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.06.020_bib17","article-title":"Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome","volume":"12","author":"Mauch","year":"2023","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.ekir.2024.06.020_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100683","article-title":"Atypical hemolytic uremic syndrome treated with ravulizumab or eculizumab: a claims-based evaluation of health care resource utilization and clinical outcomes in the United States","volume":"5","author":"Wang","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2024.06.020_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12882-015-0195-1","article-title":"The global aHUS registry: methodology and initial patient characteristics","volume":"16","author":"Licht","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2024.06.020_bib20","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1007\/s00467-021-05203-8","article-title":"Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab","volume":"36","author":"Ehren","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.06.020_bib21","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.06.020_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2024.06.020_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.121883","article-title":"Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients","volume":"455","author":"Fam","year":"2023","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ekir.2024.06.020_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.06.020_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914496","article-title":"Underlying genetics of aHUS: which connection with outcome and treatment discontinuation?","volume":"24","author":"Spasiano","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2024.06.020_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.06.020_bib27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome","volume":"4","author":"Siedlecki","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.06.020_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10846","article-title":"First report on successful conversion of long-term treatment of recurrent atypical hemolytic uremic syndrome with eculizumab to ravulizumab in a renal transplant patient","volume":"35","author":"Jehn","year":"2022","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2024.06.020_bib29","first-page":"38","article-title":"Ravulizumab \u201cde novo\u201d in pediatric patients with atypical hemolitic uremic syndrome: first worldwide cases","volume":"5816","author":"Sancho","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.06.020_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001289","article-title":"Ravulizumab in preemptive living donor kidney transplantation in hereditary atypical hemolytic uremic syndrome","volume":"8","author":"Schmidt","year":"2022","journal-title":"Transplant Direct"},{"key":"10.1016\/j.ekir.2024.06.020_bib31","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ekir.2020.05.003","article-title":"Functional assessment of fatigue and other patient-reported outcomes in patients enrolled in the global aHUS registry","volume":"5","author":"Greenbaum","year":"2020","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924017960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924017960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:54:30Z","timestamp":1736502870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924017960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2468024924017960"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.06.020","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}